TransThera Sciences (HKG:2617) narrowed its attributable loss to 122.9 million yuan in the first half of 2025 from 160.4 million yuan a year prior, a Monday Hong Kong bourse filing said.

Loss per share for the clinical-stage biopharmaceutical firm was 0.32 yuan, down from 0.42 yuan in the year-ago period.

The firm did not record revenue in the period.

Other income and gains, on the other hand, fell 65.1% to 3.6 million yuan in the six months from 10.4 million yuan a year prior, mainly due to a lower interest income from bank deposits and wealth management products, as well as a decline in government grants.